Treatment of hepatitis C: a systematic review
A Kohli, A Shaffer, A Sherman, S Kottilil - Jama, 2014 - jamanetwork.com
Importance Hepatitis C virus (HCV) infects more than 185 million individuals worldwide.
Twenty percent of patients chronically infected with HCV progress to cirrhosis. New, simpler …
Twenty percent of patients chronically infected with HCV progress to cirrhosis. New, simpler …
Liver cirrhosis
EA Tsochatzis, J Bosch, AK Burroughs - The Lancet, 2014 - thelancet.com
Cirrhosis is an increasing cause of morbidity and mortality in more developed countries,
being the 14th most common cause of death worldwide but fourth in central Europe …
being the 14th most common cause of death worldwide but fourth in central Europe …
Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection
Background In phase 2 studies, treatment with the all-oral combination of the nucleotide
polymerase inhibitor sofosbuvir and the NS5A inhibitor ledipasvir resulted in high rates of …
polymerase inhibitor sofosbuvir and the NS5A inhibitor ledipasvir resulted in high rates of …
[PDF][PDF] Health care for women subjected to intimate partner violence or sexual violence: A clinical handbook
World Health Organization - 2014 - apps.who.int
Gesundheitliche Versorgung von Frauen, die Gewalt in der Paarbeziehung oder sexuelle Gewalt
erfahren Page 1 Gesundheitliche Versorgung von Frauen, die Gewalt in der Paarbeziehung oder …
erfahren Page 1 Gesundheitliche Versorgung von Frauen, die Gewalt in der Paarbeziehung oder …
Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis
Background High rates of sustained virologic response were observed among patients with
hepatitis C virus (HCV) infection who received 12 weeks of treatment with the nucleotide …
hepatitis C virus (HCV) infection who received 12 weeks of treatment with the nucleotide …
Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection
MS Sulkowski, DF Gardiner… - … England Journal of …, 2014 - Mass Medical Soc
Background All-oral combination therapy is desirable for patients with chronic hepatitis C
virus (HCV) infection. We evaluated daclatasvir (an HCV NS5A replication complex inhibitor) …
virus (HCV) infection. We evaluated daclatasvir (an HCV NS5A replication complex inhibitor) …
Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin …
E Lawitz, MS Sulkowski, R Ghalib, M Rodriguez-Torres… - The Lancet, 2014 - thelancet.com
Background Interferon-free regimens are needed to treat hepatitis C virus (HCV) infections.
We investigated the efficacy of combined simeprevir and sofosbuvir. Methods We enrolled …
We investigated the efficacy of combined simeprevir and sofosbuvir. Methods We enrolled …
[HTML][HTML] ABT-450/r–ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis
F Poordad, C Hezode, R Trinh… - … England Journal of …, 2014 - Mass Medical Soc
Background Interferon-containing regimens for the treatment of hepatitis C virus (HCV)
infection are associated with increased toxic effects in patients who also have cirrhosis. We …
infection are associated with increased toxic effects in patients who also have cirrhosis. We …
Treatment of HCV with ABT-450/r–ombitasvir and dasabuvir with ribavirin
Background The interferon-free combination of the protease inhibitor ABT-450 with ritonavir
(ABT-450/r) and the NS5A inhibitor ombitasvir (also known as ABT-267) plus the …
(ABT-450/r) and the NS5A inhibitor ombitasvir (also known as ABT-267) plus the …
ABT-450/r–ombitasvir and dasabuvir with or without ribavirin for HCV
P Ferenci, D Bernstein, J Lalezari… - … England Journal of …, 2014 - Mass Medical Soc
Background The interferon-free regimen of ABT-450 with ritonavir (ABT-450/r), ombitasvir,
and dasabuvir with or without ribavirin has shown efficacy in inducing a sustained virologic …
and dasabuvir with or without ribavirin has shown efficacy in inducing a sustained virologic …